Synlogic (NASDAQ:SYBX) Lowered to Sell at HC Wainwright

HC Wainwright downgraded shares of Synlogic (NASDAQ:SYBXFree Report) from a buy rating to a sell rating in a report released on Friday, MarketBeat.com reports. HC Wainwright also issued estimates for Synlogic’s FY2028 earnings at $7.05 EPS.

Several other equities analysts also recently commented on SYBX. Alliance Global Partners began coverage on shares of Synlogic in a research note on Monday, December 11th. They set a buy rating and a $30.00 price objective for the company. Chardan Capital cut shares of Synlogic from a buy rating to a neutral rating in a research note on Friday. Finally, SVB Leerink reissued a market perform rating on shares of Synlogic in a research note on Friday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Hold and an average price target of $65.00.

Read Our Latest Research Report on SYBX

Synlogic Stock Down 2.8 %

Shares of Synlogic stock opened at $1.72 on Friday. The business has a fifty day simple moving average of $3.45 and a 200 day simple moving average of $4.08. The stock has a market cap of $15.81 million, a PE ratio of -0.13 and a beta of 1.21. Synlogic has a 12 month low of $1.57 and a 12 month high of $13.35.

Hedge Funds Weigh In On Synlogic

Institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new position in Synlogic during the first quarter valued at $27,000. WINTON GROUP Ltd bought a new stake in shares of Synlogic in the 3rd quarter worth about $35,000. Envestnet Asset Management Inc. lifted its holdings in shares of Synlogic by 273.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 78,671 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 57,604 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Synlogic by 333.6% in the 4th quarter. Millennium Management LLC now owns 95,434 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 73,422 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Synlogic in the 1st quarter worth about $79,000. 47.18% of the stock is owned by hedge funds and other institutional investors.

About Synlogic

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

Further Reading

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.